Three steps to improve and measure your clinical trial patient diversity efforts

Over the last several years, the life sciences industry has contributed to an increased investment of time, funding, and energy in initiatives to improve the diversity of clinical trial participants. This increase in investment supports an already understood logic: that a properly diverse pool of clinical trial participants delivers the most representative set of insights regarding the safety and efficacy of a therapeutic solution. Despite this knowledge, organizations are often faced with the challenge of determining the type and level of diversity needed for clinical programs and individual studies. This is largely because diversity is an umbrella term that covers a range of characteristics including diversity of age, racial and ethnic makeup, socioeconomic status, and sex. Successfully overcoming this challenge then leads organizations to an even more daunting one: accurately measuring the performance and impact of diversity efforts toward their goals and objectives. In other words, they need to generate the appropriate evidence to demonstrate progress and improvement in this space. Even with the increase in investment, clinical teams are unclear on how to develop an optimal set of metrics to measure the success of diversity initiatives within clinical research.

In this piece, we discuss how life sciences companies can position themselves to successfully execute and measure the impact of diversity improvement initiatives within clinical trials, with insights on:

1. How to set a strategic vision for a diversity initiative that aligns with your corporate goals,
2. Best practices for creating KPIs applicable to diversity efforts, and
3. Building a culture of continuous improvement and adaptability to ensure the initiatives meet their full potential.

Read the full Clinical Leader article